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Resumo 
 
A doença de Machado Joseph (MJD), também conhecida como ataxia 
espinocerebelosa do tipo 3 (SCA3), é a ataxia espinocerebelosa mais comum em todo o 
mundo. Esta doença é causada por uma repetição excessiva do trinucleótido CAG no gene 
MJD1/ATXN3, que se traduz num tracto de poliglutaminas na proteína ataxina-3. Até ao 
momento não existem terapias que sejam capazes de modificar ou atrasar a progressão 
desta doença fatal. No entanto, as células mesenquimatosas do estroma (MSC) têm 
demonstrado ser uma ferramenta promissora como terapia celular de doenças 
neurodegenerativas. Recentemente, o seu uso tem vindo a receber especial atenção em 
doenças que afectam o cerebelo, nomeadamente em ataxias espinocerebelosas. Estudos pré-
clínicos e clínicos têm demonstrado que a utilização deste tipo de células é segura e que 
contribui para a melhoria de doentes com ataxias. No entanto, não existem ainda estudos 
que avaliem o uso das MSC em MJD usando modelos animais. Os estudos em humanos 
estão confinados a avaliação clinica e não permitem avaliar a neuropatologia antes e após a 
administração das MSC. Torna-se assim crucial o estudo do uso das MSC num modelo de 
murganhos portadores da MJD para investigar se a terapia pode aliviar o comprometimento 
motor e a neurodegeneração causada pela ataxina-3 mutante.  
 No presente estudo investigámos se o transplante local das MSC no cerebelo de 
murganhos transgénicos portadores de MJD poderia produzir um efeito neuroprotector e 
aliviar o fenótipo inerente a esta doença. Foi demonstrado que as MSC conseguem 
sobreviver no tecido cerebelar e produzir uma melhoria na coordenação motora. Além 
disso, as MSC conseguiram aliviar a neuropatologia neste modelo de MJD, preservando as 
células de Purkinje e as camadas molecular e granular do cerebelo. Em conclusão, estes 
resultados sugerem que a terapia com MSC pode tornar-se uma forte abordagem 
terapêutica para a doença Machado Joseph. 
 
 
 
Palavras-chave: Ataxia espinocerebelosa do tipo 3; Doença de Machado Joseph; Células 
mesenquimatosas do estroma; transplante; modelo MJD. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General Introduction 
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1. Polyglutamine diseases  
 
Polyglutamine (polyQ) diseases are a group of 9 inherited neurodegenerative disorders 
associated with the expansion of a CAG triplet repeat in the respective causative gene. This 
group of disorders includes Huntington's disease (HD), dentatorubral-pallidoluysian atrophy 
(DRPLA), spinal bulbar muscular atrophy (SBMA), and the spinocerebellar ataxias 1, 2, 3, 6, 7 
and 17. With the exception of SBMA which is X-linked, all other polyQ diseases are 
dominantly inherited disorders (Havel et al., 2009). All polyQ diseases share several common 
features: they are progressive, typically striking in midlife, and cause increasing neuronal 
dysfunction and eventual selective neuronal loss usually 10–20 years after the onset of 
symptoms. The whole process is accompanied by severe physical and psychological 
complications (Zoghbi et al., 2000). Other common aspect to all polyQ diseases is the 
inverse correlation between the age of onset and the number of CAG repeats, leading to 
earlier onset when there is a greater number of repeats (Dürr et al., 1996, Maciel et al., 
1995, Matos et al., 2011, Ranum et al., 1995, Riess et al., 2008, Zoghbi and Orr, 2000). The 
polyQ tract is highly polymorphic and the CAG expansion above a certain length threshold 
confers toxicity (James et al., 2000, Paulson, 1999, Zoghbi and Orr, 2000). Besides the polyQ 
tract, proteins associated with different disorders share no homologies, being structurally 
and functionally unrelated to each other (Gatchel et al., 2005, Zoghbi and Orr, 2000). This 
suggests that the polyQ stretch itself confers toxic properties to these proteins through a 
“toxic gain of function”, thus indicating a possible common mechanism of pathogenesis 
(Nagai et al., 2007b). 
 
1.1. Spinocerebellar ataxias 
Spinocerebellar ataxias (SCAs) are a heterogeneous group of typically late-onset (usually 
between 30 and 50 years of age) autosomal dominant inherited ataxias and consist on 
progressive neurodegenerative disorders that evolve to a fatal state (Carlson et al., 2009, 
Dueñas et al., 2006). These disorders are characterized by variable degrees of degeneration 
of the cerebellum, often accompanied by changes in the brainstem and spinal tracts.  Patients 
present progressive gait and limb ataxia as the main clinical feature, which is usually 
accompanied by signs and symptoms that reflect damage beyond the cerebellum and 
including its afferent and efferent pathways (Paulson, 2009, Schöls et al., 2004). SCAs are rare 
diseases, whose prevalence estimates vary from 0.3 to 2.0 per 100,000 (van de Warrenburg 
et al., 2002).  
3 
2. Machado Joseph disease/Spinocerebellar ataxia 3  
Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), is a 
polyQ disease whose CAGn trinucleotide repeat expansion is localized in the MJD1/ATXN3 
gene, encoding for a tract of glutamine repeats in the ataxin-3 protein. It was originally 
described in people of Portuguese Azorean descent by Nakano et al. (1972) who initially 
named this ataxia as “Machado disease” (Nakano et al., 1972). Later, 3 more families were 
reported to have the same disease and this led to different designations: “nigro-spino-
dendatal degeneration with ophtalmoplegia” (Woods et al., 1972), “Joseph disease” 
(Rosenberg et al., 1976) and “Azorean disease” (Romanul et al., 1977). Later, it was proposed 
the name “Machado Joseph disease” for all the previously described clinical entities. It was 
defined as a single disorder accompanied by an unusually high degree of clinical variability 
(Coutinho et al., 1978, Lima et al., 1980).  
At the moment, MJD is known to be the most common form of autosomal dominant 
ataxia worldwide (Schöls et al., 2004). It has a higher relative frequency in countries such ias 
Brazil, Portugal, Singapore, the Netherlands, Germany and Japan, but within each country the 
geographic distribution is heterogeneous. For instance, in Portugal, MJD is relatively rare in 
the mainland, but highly prevalent in the Azores Islands, especially within Flores, where the 
highest worldwide prevalence occurs (Bettencourt et al., 2011, Bettencourt et al., 2008) (Fig. 
I).  
 
Figure I - Worldwide distribution of SCAs. Abbreviations: SCAs, spinocerebellar ataxias. Adapted from  
(Bird, 1993).  
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2.1. Molecular/genetics features and pathogenesis  
 
2.1.1. The MJD1/ATXN3 gene 
In 1993, Takiyama et al. first mapped the locus responsible for MJD in the long arm of 
chromosome 14 (14q32.1) and in the next year Kawaguchi et al. cloned the MJD1/ATXN3 
gene, previously mapped, and showed that an unstable CAG repeat expansion motif was 
present in all MJD patients (Kawaguchi et al., 1994, Takiyama et al., 1993). Later, Ichikawa 
and colleagues described the genomic structure of MJD gene (Ichikawa et al., 2001). The 
gene was found to contain 11 exons, spanning about 48 kb, with the (CAG)n tract located at 
the exon 10. They also reported 4 different species of transcripts, ubiquitously expressed in 
neuronal and non-neuronal human tissues with different sizes, which were thought to result 
from differential splicing events of exons 10 and 11 and alternative polyadenylation of exon 
11 (Ichikawa et al., 2001). More recently, 2 additional exons - 6a and 9a - were described, 
and it is now known that a large number of splicing variants exist (about 50), which are 
generated by 4 types of splicing events occurring in a simple or combined way (Bettencourt 
et al., 2010).  
Currently named as ATXN3 (but MJD and MJD1 are still in use), this gene encodes for 
ataxin-3 protein, which contains a polyQ tract at the C-terminus encoded by the CAGn 
trinucleotide repeat. CAG repeats are unstable, so in healthy population the number range 
from 10 and 51 repeats, whereas in MJD patients it ranges from 55 to 87 repeats 
(Bettencourt and Lima, 2011, Kawaguchi et al., 1994, Maciel et al., 2001, Nóbrega et al., 
2012). Cases of homozygosity are rare in MJD, but when described patients show a more 
severe form of disease (Carvalho et al., 2008, Lang et al., 1994). 
 
2.1.2. Ataxin-3 protein 
Ataxin-3 is an intracellular deubiquitinating (DUB) enzyme belonging to the group of 
cysteine proteases, with an overall molecular weight of 42 kDa (Kawaguchi et al., 1994). 
This protein is widely expressed in various tissues and different cell types, displaying a 
ubiquitous expression throughout the brain, though different brain regions present variable 
levels of expression. Regarding its subcellular localization, ataxin-3 has been reported to 
exist both in the cytoplasm and in the nucleus, and even in mitochondria, but its localization 
is predominantly cytoplasmatic (Paulson et al., 1997a, Pozzi et al., 2008, Schmidt et al., 1998, 
Trottier et al., 1998). 
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2.1.2.1. Structure and domains 
The human ataxin-3 was originally reported to be composed of 339 amino acid residues 
plus a variable number of glutamine repeats. This protein contains a conserved/structured 
globular N-terminal Josephin domain followed by an unstructured, flexible C-terminal tail 
containing 2 or 3 ubiquitin-interaction motifs (UIMs), depending on the protein, which binds 
polyadenylated proteins with preference for tetraubiquitin or polyubiquitin chain, and the 
polyQ region of variable length (Albrecht et al., 2004, Burnett et al., 2003, Goto et al., 1997, 
Kawaguchi et al., 1994, Masino et al., 2003). 
A highly conserved, putative nuclear localization signal (NLS) was found upstream of 
polyQ stretch (Albrecht et al., 2004, Tait et al., 1998). It was also found 2 nuclear export 
signals, NES77 and NES141 that coincide with the Josephin domain. There is the hypothesis 
that another NES (NES 174), localized following the Josephin domain, can also influence the 
nuclear export activity (Albrecht et al., 2004, Antony et al., 2009) (Fig. II).  
 
 
 
Figure II - Schematic representation of ataxin-3 protein structure. Ataxin-3 contains a conserved 
Josephin domain followed by a flexible C-terminal tail containing 2 or 3 UIMs and a polyQ sequence of variable 
length. One functional NLS was described upstream of polyQ stretch and 3 NES were reported in the ataxin-3. 
Abbreviations: NES, nuclear export signal; NLS, nuclear localization signal; PolyQ, polyglutamine; UIMs - 
ubiquitin-interaction motifs. 
 
2.1.2.2. Functions 
Although the biological function of ataxin-3 has not yet been completely understood, this 
protein seems to participate in many cellular pathways. There is evidence that ataxin-3 can 
be involved in many cellular protein quality control mechanisms, operating through the 
ubiquitin-proteasome system (UPS) (Doss-Pepe et al., 2003), i.e. ataxin-3 can edit the 
ubiquitin chain production by ubiquitin ligases and trim heavily ubiquitinated species, thus 
regulating the ubiquitination status of proteins before their presentation to the proteasome. 
(Paulson, 2012). After interacting with ubiquitined proteins, ataxin-3 interacts with others 
proteins, participating in substrate delivery to the proteasome (Doss-Pepe et al., 2003). 
Ataxin-3 was also associated with the endoplasmic reticulum-associated degradation 
(ERAD) system, which is responsible for the ubiquitination of misfolded proteins and their 
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exportation into the cytosol for degradation by the UPS (Albrecht et al., 2004, Burnett et al., 
2003, Meusser et al., 2005, Zhong et al., 2006). 
As a quality control protein, ataxin-3 has also been reported to regulate the aggresomes 
formation. Aggresomes are formed by misfolded proteins, which are transported to 
perinuclear localization, near to the microtubule-organizing center (MTOC). It was shown 
that endogenous ataxin-3 co-localizes with cytoplasmic aggregates/pre-aggresome particles 
and associates with components of the complex that transports misfolded proteins to the 
MTOC, histone deacetylase 6 and dynein. It has been proposed that ataxin-3 is recruited to 
bind and trim ubiquitin chains on misfolded ubiquitinated proteins, protecting them before 
they reach the MTOC for aggresome formation or it may use its DUB activity to stabilize 
proteins involved in the trafficking of misfolded proteins (Burnett et al., 2005). 
Ataxin-3 has been also associated with the cellular organization of the cytoskeleton, once 
in its absence cells display cytoskeletal and adhesion defects, with fewer projections, 
cytoskeletal disorganization, loss of adhesion and increased cell death; moreover, it can 
interact with components of the cytoskeleton, such as tubulin, MAP2 and dynein 
(Mazzucchelli et al., 2009, Rodrigues et al., 2010). Considering myogenesis, ataxin-3 appears 
to be critical for the regulation of integrin subunit levels and once more for the organization 
of the cytoskeleton (do Carmo Costa et al., 2010, Mayer, 2003). 
Other possible function of ataxin-3 is transcription regulation, as it can bind DNA and 
interact with transcriptional factors. It has been reported that ataxin-3 interacts with 
transcription activators and repressors, through its UIM and histones, at the N-terminal 
region (Evert et al., 2006, Li et al., 2002). In case of transcription activators, ataxin-3 seems 
to repress their activity by binding them through its C-terminal region. Histones are bonded 
to the N-terminal region of ataxin-3 and this represses acetylation, since histone acetylation 
sites are blocked. It was shown that ataxin-3 together with some transcription repressors 
can decrease histone acetylation and repress transcription (Li et al., 2002, Nicastro et al., 
2005). Thus, the involvement of ataxin-3 in transcriptional regulation might be coupled to its 
DUB activity, since this activity may interfere with the turnover of transcriptional regulators, 
thereby influencing the repressor complex formation and subsequent activity (Evert et al., 
2006, Rodrigues et al., 2007). 
 
2.2. Clinical features 
MJD is characterized by progressive ataxia, but ataxia by itself never occurs alone, since 
this disease involves various systems such as the cerebellar, pyramidal, extrapyramidal, 
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motor neuron and oculomotor systems. So, beyond cerebellar ataxia that can affect gaze, 
speech, gait, and balance, the typical signs include: progressive external ophthalmoplegia, 
dysarthria, dysphagia, pyramidal signs, dystonia, rigidity and distal muscle atrophies 
(Bettencourt and Lima, 2011, Lima and Coutinho, 1980, Paulson, 2007, Paulson, 2012, Taroni 
et al., 2004). There is also clinical data showing that a non-motor involvement can also affect 
MJD patients including sleep disorders, cognitive, affective and psychiatric disturbances, 
olfactory dysfunction and peripheral neuropathy (Pedroso et al., 2013).  
The age of disease onset is highly variable. Though symptom onset usually occurs around 
40 years, MJD was already reported either in young people (beginning as early as at 4 years 
old) or in old people (starting at 70’s) (Bettencourt and Lima, 2011, Paulson, 2012). 
 
2.3. Neuropathology  
The MJD neuropathology involves neuronal loss in specific brain regions, such as basal 
ganglia, brainstem and the cerebellum. Dysfunction and degeneration have been observed in 
the whole cerebellum, cerebellar hemispheres and vermis (spinocerebellar pathways and 
dentate nucleus), whole brainstem (including midbrain, pons and medulla), basal ganglia 
(globus pallidus, caudate and putamen), thalamus, substantia nigra, striatum, pontine nucleus, 
spinal cord (including anterior horn cells and Clarke’s column) and cranial nerves (III-XII), as 
well as the visual, auditory, vestibular, somatosensory and urination-related systems. Other 
structures such as cerebral and cerebellar cortex, inferior olive and Purkinje cells are 
relatively spared. Furthermore, metabolic abnormalities such as axonal dysfunction and 
glucose utilization deficits in cerebellum, brainstem and cerebral cortex were suggested to 
occur. Involvement of both the dopaminergic and the cholinergic systems have been also 
reported (Bettencourt and Lima, 2011, Costa et al., 2012, Coutinho and Andrade, 1978, 
Dürr et al., 1996, Matos et al., 2011, Nóbrega and de, 2012, Paulson, 2012, Riess et al., 2008, 
Rub et al., 2008, Schulz et al., 2010, Sudarsky et al., 1995) (Fig. III).  
The majority of the brains from MJD patients with advanced disease stage present low 
weight when compared with brains from individuals without any neurological or psychiatric 
disease (Iwabuchi et al., 1999, Rub et al., 2007). 
A neuropathologic hallmark of MJD is the presence of neuronal intranuclear inclusions 
(NIIs) in brain, which results from the nuclear accumulation of mutant polyQ proteins. NIIs 
are spherical and eosinophilic structures and their size vary from 0.7 to 3.7 µm; they are 
non-membrane bound elements, heterogeneous in composition, and contain a mixture of 
granular and filamentous structures. Various proteins are found within the inclusion, both 
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normal and pathogenic ataxin-3, as well as ubiquitin, molecular chaperones, proteasomal 
components, transcription factors and other polyQ proteins. These NIIs can be present in 
both affected and unaffected brain regions, and the cytotoxicity of NIIs is controversial (Chai 
et al., 1999a, Chai et al., 1999b, Paulson et al., 1997b, Schmidt et al., 1998, Schmidt et al., 
2002, Yamada et al., 2000). In addition, extranuclear accumulation in MJD brain and neuronal 
cytoplasmatic inclusions (NICs) containing mutant ataxin-3 have also been reported. These 
inclusions are composed by fine granules with about 1.5 µm in diameter, ubiquitin-negative 
and exhibit a similar distribution as the NIIs (Hayashi et al., 2003, Yamada et al., 2008, 
Yamada et al., 2004, Yamada et al., 2002). 
 
 
Figure III - Pathological features of SCA3. Schematic representation indicating the principal sites of 
neuronal loss and organ dysfunction in SCA3. Large dots indicate severe neuronal loss. Blue dots indicate 
involvement of extrapyramidal nuclei. Green dots indicate cranial nerve involvement. Abbreviations: SCA3, 
spinocerebellar ataxia type 3. Adapted from (Taroni and DiDonato, 2004).  
 
2.4. Pathogenesis 
The molecular basis of MJD is still poorly understood. However, several cellular and 
molecular mechanisms have been proposed for MJD pathology. It has been observed that 
expansion of the polyQ tract in ataxin-3 affects its properties through a conformational 
change, acquiring toxic properties, which can result in altered molecular interactions. The 
common feature among polyQ diseases is the presence of neuronal inclusions (NIs) 
containing the mutant protein, thus suggesting that misfolded proteins are pathological 
features. The abundance of these neuronal inclusions has been correlated to the CAG 
repeat size and disease severity and it has been proposed that they could also impair axonal 
transport and nuclear function (Nóbrega and de, 2012, Paulson et al., 1997b). Moreover, NIs 
may compromise the recruitment of several key proteins such as transcription factors, 
proteasomal components and chaperones, thus affecting various cellular pathways (Chai et 
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al., 1999a, Chai et al., 1999b, McCampbell et al., 2000, Paulson et al., 1997b, Schmidt et al., 
2002). Besides NIs, it has been shown that polyQ monomers of ataxin-3 acquire β-strand 
conformations and later assemble into oligomers. These β-rich ataxin-3 monomers and 
oligomers may be toxic for cells in MJD (Bevivino et al., 2001, Nagai et al., 2007a, Takahashi 
et al., 2008). 
It has been reported that the proteolytic cleavage of expanded polyQ ataxin-3 results in 
smaller toxic fragments containing an expanded polyQ tract, facilitating the entry from 
cytoplasm into the nucleus (Haacke et al., 2006, Haacke et al., 2007, Simões et al., 2014) and 
contributing for aggregation and cytotoxicity (Simões et al., 2012). 
Mutant ataxin-3 could also contribute for the impairment of cellular quality control 
system, impairment of axonal transport, transcription deregulation, mitochondrial 
dysfunction (it was reported that mutant ataxin-3 decreases the activity of antioxidant 
enzyme causing damage of mitochondrial DNA); oxidative stress and calcium homeostasis 
deregulation (Costa and Paulson, 2012, Nóbrega and de, 2012, Yu et al., 2009). 
Another important aspect is neuroinflammation. It was demonstrated an upregulation of 
some inflammatory genes, such as the pro-inflammatory cytokine interleukin-1 β, when 
mutant ataxin-3 was present, suggesting that glia might also contribute to pathogenesis 
(Evert et al., 2001, Evert et al., 2003)(Fig.IV).  
  
 
  
Figure IV - Mechanisms of pathogenesis in MJD. Abbreviations: MJD, Machado Joseph disease. 
Adapted from (Nóbrega and de, 2012)  
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3. Multipotent mesenchymal stromal cells  
Multipotent mesenchymal stromal cells (MSC) are multipotent adult stem cells (Caplan, 
1991) that were originally found in the stroma of bone marrow by Alexander Friedenstein in 
1970s. He and his colleagues described it as a rare population of plastic-adherent cells 
(constituting only 0.01-0.001% of the total nucleated cells in the bone marrow) with a 
fibroblast-like appearance that could generate colonies called as CFU-Fs (“colony forming 
unit fibroblastic cells”) (Friedenstein et al., 1970, Friedenstein et al., 1974).  
These cells can also be isolated from other type of tissues, such as brain, liver, bone and 
adipose tissue, skeletal muscle, teeth, pancreas, lung, amniotic fluid, hair follicle, or umbilical 
cord, and they have been isolated from many species including human, mouse, rat, dog, and 
horse (Drela et al., 2013, Rastegar et al., 2010). In the bone-marrow, MSC are included into 
the stromal system and their functions are: to maintain a certain level of self-renewal, give 
rise to cells that can differentiate into various connective tissue lineages, produce 
extracellular matrix proteins and additional soluble molecules to promote haematopoiesis 
support. It is likely that MSC serve cellular functions similar to pericytes that surround bone 
marrow sinusoids (Bianco et al., 2001, Deans et al., 2000, Parekkadan et al., 2010) (Fig. V).    
Several names for the MSC have been reported, such as “CFU-F”, “stromal stem cells”, 
“marrow stromal cells”, and “mesenchymal stem cells”. To clarify the nomenclature of the 
MSC, the committee of the International Society for Cellular Therapy proposed that MSC 
should be termed “multipotent mesenchymal stromal cells” and “mesenchymal stem cell” 
should be reserved for cells that demonstrate stem cell activity (long-term self-renewing 
cells that are capable of differentiation into specific, multiple cell types from different lineages 
in vivo). The terminology should also include the source of MSC, for instance adipose-derived 
MSC, bone marrow-derived MSC, etc. (Horwitz et al., 2005). 
 
11 
 
 
Figure V - Natural functions of MSC in the bone marrow. Abbreviations: ECM, extracellular matrix; MSC, 
multipotent mesenchymal stromal cells. Adapted from (Parekkadan and Milwid, 2010). 
 
3.1. Phenotypic characterization and other key features 
MSC are primitive cells originated from the mesodermal germ layer, characterized by 
their self-renewal potential and their potential for differentiation into multiples mesenchymal 
lineages, such as bone, adipose tissues, cartilage, tendon, muscle and other connective tissues 
(Baksh et al., 2004, Caplan et al., 2006, Salem et al., 2010) (Fig VI).  
Traditionally, MSC present a spindle-shaped, but it is know that there is MSC 
heterogeneity either in their morphology, containing cells ranging from narrow spindle-shape 
to large polygonal cells, or in terms of cell size, multipotency and marker expression 
(Chamberlain et al., 2007, Mabuchi et al., 2013).  
Regarding phenotypic MSC characterization, there is lack of a unique marker to 
characterize these cells. Thus, The Tissue Stem Cell Committee of International Society for 
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Cellular Therapy proposed 3 minimum criteria to define human MSC: 1) plastic 
adherence - when maintained in standard culture conditions; 2) specific surface antigen 
expression - ≥95% of the MSC must be positive for the expression of CD105 (endoglin), 
CD73 (ecto-5’-nucleotidade), and CD90 (Thy-1 thymocyte differentiation antigen-1); and 
must lack expression (5/2% positive) of hematopoietic cell surface markers, CD45 
(leukocyte common antigen), CD34 (primitive hematopoietic progenitors and endothelial 
cells antigen), CD11b or CD14 (monocytes and macrophages antigen), CD19 (B cells  
antigen), and HLA (human leukocyte antigen) or MHC (major histocompatibility) class II; 3) 
multipotent differentiation potential - MSC must be able to differentiate into 
osteoblasts, adipocytes and chondroblasts (Dominici et al., 2006).  
Nonetheless, MSC isolated from other species do not express the same markers as those 
of human cells.  For instance, CD34 is rarely expressed in human and rat MSC but their 
expression is variable on murine MSC. Furthermore, there are differences among murine 
MSC from different strains, for example in CD34, Sca-1 (stem cell antigen 1), and CD106 or 
VCAM-1 (vascular cell adhesion molecule I) expression (Chamberlain et al., 2007, Kolf et al., 
2007, Peister et al., 2004). Nonetheless there is a list of markers that are more commonly 
used to characterize murine MSC isolated from C57BL/6 mice such as CD29, CD44, CD73, 
CD105, CD106, CD44, and Sca-1 (Baddoo et al., 2003, Mabuchi et al., 2013, Morikawa et al., 
2009, Sun et al., 2003).  
 
 
Figure VI -   MSC have the potential to differentiate into a wide range of cell types mesodermal lineages. 
Abbreviations: MSC, multipotent mesenchymal stromal cells. Adapted from (Anissa S.H. Chan, 2007). 
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3.2. Localization, Homing and Trafficking 
There is evidence that MSCs are not restricted to the bone marrow, but otherwise are 
localized in niches within various tissues. It has been proposed that MSC are identical to or 
are related to pericytes, because they share surface and intracellular protein expression 
patterns and differentiation capacity features. Pericytes are mural cells, with branched shape, 
located on the abluminal side of small blood vessels (arterioles, capillaries and venules) and 
they are connected with endothelial cells. This proximity to vessel would allow pericytes to 
quickly enter the bloodstream; thus, this perivascular localization of MSC within niches 
throughout the body allow them to easily access to all tissues and promote repair of local 
small lesions (Augello et al., 2010, Kolf et al., 2007, Parekkadan and Milwid, 2010, Paul et al., 
2013, Salem and Thiemermann, 2010).  
MSC have a unique homing capacity, targeting injured or/and inflamed tissues. This process 
consists on cells migration to and engraftment in the injured tissues in which they will exert 
protective effects (Salem and Thiemermann, 2010).  The exact mechanism by which MSC 
home to specific tissues is not yet fully understood, but it has been proposed that this 
mechanism is identical to the multistep process by which leukocytes migrate to inflamed 
sites, since MSC express some adhesion molecules in common with leukocytes, such as 
CD44 (homing cell adhesion molecule), CD49a-f (very late antigen-α1-6), CD29 (very late 
antigen-β chain) and CD18 (leukocyte function-associated antigen-1β chain) (Kavanagh et al., 
2014, Salem and Thiemermann, 2010, Sohni et al., 2013).  Homing is dependent on chemokines 
and chemokine receptors expressed by injured tissues; since MSC express various receptors 
for these chemokines, they answer to the gradient of inflammatory chemokines and home to 
the inflammation site (Salem and Thiemermann, 2010).  
 
3.3. MSC application for neurodegenerative diseases 
In the last years, MSC have been demonstrating promising results in regenerative 
medicine including in neurodegenerative diseases. There are many reasons why MSC have 
been used in cell therapy: they are easily isolated and can be expanded ex vivo to clinical 
scales in a relative short period of time. Besides that, they can be cryopreserved with minimal 
loss of potency and used later in transplants, allowing their use in the real clinical world 
(Parekkadan and Milwid, 2010, Teixeira et al., 2013).  Moreover, it has been reported that MSC 
possess low immunogenicity, allowing their use in both autologous and allogeneic transplants. 
They are also considered non tumorigenic, as they have been used in many in vivo 
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transplantation procedures without tumour formation (Parekkadan and Milwid, 2010, Sadan 
et al., 2009). In addition to their safety features, MSC can home to injured tissues and secrete 
chemokines and growth factors among other molecules, which help the tissues to recovery 
from the lesion (Chamberlain et al., 2007, Sohni and Verfaillie, 2013).   
 
3.3.1. Possible mechanism of action 
Several mechanisms have been proposed to explain the positive MSC effect in 
neurodegenerative diseases. The first mechanism is based on the transdifferentiation concept 
(differentiation of MSC into cells from the neural lineage), allowing the direct replacement of 
damaged cells. Another possible mechanism is the fusion between MSC and local endogenous 
neural cells in which MSC acquire the phenotype features of neural cells. The last possible 
mechanism is MSC secretion of soluble factors that stimulate resident neural cells to repair 
and/or enhance neurogenesis (Drela et al., 2013, Maltman et al., 2011) (Fig.VII).  
 
 
 
Figure VII - Possible mechanisms of MSC in neurodegenerative diseases.  1) Transdifferentiation – 
differentiation of MSC into neural/glial cells; 2) Paracrine effect – secretion of neurotrophic factors, cytokines, 
chemokines, interleukines and ECM proteins, which affect neuronal cells; 3) Cell fusion – fusion between MSC 
and neuronal cells, acquiring the neural phenotype. Abbreviations: ECM, extracellular matrix; MSC, 
multipotent mesenchymal stromal cells.  
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3.3.1.1. Transdifferentiation 
It has been demonstrated that some adult stem cells are capable to differentiate into 
many cell types and tissue lineages of different germ layers from the one in which these stem 
cells reside. This plastic ability is commonly called “transdifferentiation” (Krabbe et al., 2005). 
MSC have also been reported as being able to differentiate into cells of both endodermal 
(hepatocytes) and ectodermal lineages (neural cells) beyond their mesodermal origin, when 
in the presence of specific growth factors and very defined conditions (Fernández Vallone et 
al., 2013).  
There are many reports referring different in vitro protocols showing MSC 
transdifferentiation into neuronal and/or glial cells using chemical induction (supplementation 
of differentiation media with simple or cocktails of small molecules or chemicals), treatment 
with various growth factors and neurotrophic molecules, gene transfection with specific gene 
expression, or co-culture of MSC with neural cells (direct cell-cell interaction and/or 
interplay by soluble factors) (Maltman et al., 2011, Ries et al., 2012).  
Although various reports demonstrated that MSC can give rise to neural-like cells - since 
they adopt the morphology of neurons, such as retractile cell bodies and long branching 
processes, and express both immature and mature neuronal markers, under differentiating 
conditions (Jiang et al., 2010, Tropel et al., 2006) - there are some doubts over MSC 
differentiation along neural lineage that result from specific in vitro differentiation protocols. 
The neuronal differentiation is a complex process that in vivo requires the temporal and 
spatial regulation of a wide array of genes and it is unlikely that it can occur in a short time, 
as is reported in various studies using the chemical induction (Lu et al., 2004, Maltman et al., 
2011, Ries and Egea, 2012, Zurita et al., 2008).  
Furthermore, it has been described that MSC have predisposition to express neural 
markers.  In basal conditions, undifferentiated MSC can already express neuronal genes, such 
as nestin, microtubule associated protein 1b (MAP1b), neuronal nuclei (NeuN), neuron-
specific enolase, and β-III tubulin. This fact may contribute to the controversy about the 
differentiation capacity of MSC or may explain why it can be thought that MSC integrate the 
central nervous system (CNS) and differentiate into neural and/or glial cells when exposed 
to the neuronal environment (Blondheim et al., 2006, Deng et al., 2006a, Montzka et al., 
2009). 
As conclusion, morphological features and neuronal marker expression analysis is not 
enough to evaluate MSC differentiation toward neural cells in vitro. Besides that, it is 
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important to simultaneously assess functional electrophysiological parameters and synaptic 
transmission (Jin et al., 2003, Krabbe et al., 2005, Wislet-Gendebien et al., 2005).  
In vivo MSC differentiation into neural and/or glial cells has also been reported. According 
to these studies, MSC injected into the CNS are able to survive, engraft and migrate. It has 
been reported that transplanted MSC express neural markers, leading to think that 
transdifferentiation can be the mechanism responsible for functional improvement exerted 
by MSC (Azizi et al., 1998, Kopen et al., 1999). However, in vivo transdifferentiation is unlikely 
to occur and it is not probable that this mechanism would be responsible by its one for the 
beneficial effect of MSC. Besides the number of MSC which engraft and express this neural 
markers being very low (Deng et al., 2006b), these studies commonly describe 
transdifferentiation by immunohistochemical protocols, which is doubtful, since transplanted 
cells can already express this markers in vitro, under basal conditions. It is then essential to 
evaluate functional integration of MSC in the neural tissue and as a proof of concept, 
elucidate the mechanism by which transdifferentiation would occur (Maltman et al., 2011).  
 
3.3.1.2. Cell Fusion 
Another alternative mechanism proposed for MSC’s action is spontaneous fusion 
between transplanted MSC and host cells, although only a few studies have demonstrated 
this phenomenon. 
Specifically considering the case of neurodegenerative diseases affecting the cerebellum, it 
was reported that upon human MSC intravenous (IV) injection into mice with experimental 
autoimmune encephalomyelitis (EAE) these cells migrate to the cerebellum and fuse with 
Purkinje cells. It was however reported that these fusion events are increased in the case of 
EAE, resulting as a response to neuroinflammation and stress microenvironment (Kemp et al., 
2011). In another study, the injection of bone marrow-derived MSC (BM-MSC) into the right 
retro-orbital sinus in a mouse model of SCA1, showed that MSC can be detected in the 
cerebellum and can fuse with host Purkinje neurons. Besides that, it was demonstrated that 
mice treated with BM-MSC presented a decrease in the number of nuclear inclusions, 
demonstrating the beneficial potential effects of MSC in this particular disorder (Chen et al., 
2011).  
However, spontaneous cell fusion was reported as a phenomenon with very low 
frequency (2–11 clones per 106 bone marrow cells) (Terada et al., 2002). Thus, although this is 
a possible mechanism by which MSC mediate neural functional recovery, its contribution is 
likely to be minor (Maltman et al., 2011).  
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3.3.1.3. Paracrine effect 
There is significant evidence that MSC secrete bioactive factors (including extracellular 
vesicles and soluble factors), which are associated with their regenerative effect. These 
molecules confer  MSC their unique capacity to interact with cells from the immune system 
and/or directly or indirectly stimulate endogenous repair mechanisms (Dorronsoro et al., 
2013, Lavoie et al., 2013, Paul and Anisimov, 2013)  and include: neurotrophic factors, 
chemokines, interleukins or cytokines, and extracellular matrix proteins (Maltman et al., 2011, 
Paul and Anisimov, 2013). 
The neurotrophic factors that are most commonly secreted by MSC are: the proteins 
nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived 
neurotrophic factor (GDNF), neurotrophin-3 (NT-3), basic fibroblast growth factor (bFGF), 
vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and ciliary 
neurotrophic factor (CNTF) (Chen et al., 2005). These molecules/factors have been described 
as being involved in crucial mechanisms such as neuronal proliferation, survival and 
differentiation, neuritogenesis, and protection against apoptosis (Teixeira et al., 2013).  
Additionally, several ILs such as IL-6, -7, -8, -11, -12, -14 and 15, have been reported as 
important elements during the neural development. Other molecules similarly associated to 
MSC are extracellular matrix proteins, including collagen, laminin and fibronectin (Nakayama 
et al., 2003). These have been showed to be an important support for neurogenesis and play a 
direct trophic role in the neural niche (Maltman et al., 2011).  
On the other hand, MSC present a unique immunomodulatory capacity; they are capable 
of inducing immunosuppressive effects in innate and adaptive immune cells and to modulate 
the inflammatory response mediated by the action of ILs, chemokines, chemokine receptors 
or cytokines (Dorronsoro et al., 2013, Kassis et al., 2011). MSC were found to interact with 
almost all populations of immune cells: T and B cells, natural killer cells (NK), regulatory T 
cells (Treg) and dendritic cells (DC) (Dorronsoro et al., 2013, Kassis et al., 2011, Nauta et al., 
2007, Uccelli et al., 2006).  
Lastly, a special attention has been recently given to the secretion of exosomes by MSC. 
Exosomes are microvesicles that are released to the extracellular space which can contain, 
among other molecules, proteins and RNAs (Yu et al., 2014).  It is known that MSC can 
produce higher amount of exosomes than other cell types and because of that, they were 
suggested to become a good tool for drug delivery or to facilitate gene and cell therapy. 
However, this approach is still unexplored and untested (Lai et al., 2013, Yu et al., 2014).  
18 
In conclusion, the secretory features of MSC can be used to promote functional recovery 
of CNS injury or inflammation, making them an excellent candidate for neurodegenerative 
disease therapies. 
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4. MSC application for PolyQ diseases 
MSC therapy has been commonly used in some polyQ disorders, namely in HD and 
SCAs.  
Lin et al. used human BM-MSC (hBM-MSC) to investigate their therapeutic potential in an 
HD mouse model induced by quinolic acid injections in the striatum. HD mice were then 
transplanted in the striatum with hBM-MSC. Cells were capable to engraft into the 
compromised striatum, reduce the motor function impairment and increase mice survival 
rate, since BM-MSC-treated animals presented improvements in striatal volume, rotarod 
performance and surviral rates compared with non-treated controls. These authors also 
tested BM-MSC transplantation in R6/2-J2, a genetically-modified animal model of HD, and 
obtained similar outcomes, concerning the survival rates and striatum volume (Lin et al., 
2011).  
In another study, rat BM-MSC were transplanted in the striatum after quinolinic acid 
injection in Wistar rats. The authors demonstrated that BM-MSC could be detected until 60 
days after implantation in the injured striatum and they could reduce striatal 
neurodegeneration and decrease ventriculomegaly, demonstrating that MSC may be a 
promising therapy in HD (Moraes et al., 2012).  
Furthermore, Rossignol et al. compared the transplantation of BM-MSC, adult neural 
stem cells (aNSC), or co-transplantation of MSC and aNSC in a transgenic rat model for 
HD. They showed that either adult stem cells by itself or co-transplantation could retard the 
progression of motor deficits (demonstrated through rotarod test). It was also 
demonstrated that both MSC and aNSC could engraft as the cells were detected in the site 
injection, but the graft area was bigger in the case of the MSC-treated group. Interestingly, 
the co-transplantation enhanced the survival of the aNSC graft, suggesting that MSC can 
create a microenvironment capable to prolong aNSC survival and provide greater 
behavioural improvements (Rossignol et al., 2014).  
As shown above, the outcomes obtained in HD are very encouraging, as the results 
demonstrated that MSC can ameliorate the deficits present in HD mouse models. 
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4.1. MSC therapy in ataxias 
In ataxias, MSC’s effect is equally promising, as there have been reports suggesting safety 
and delay in disease progression in some SCAs, namely SCA 1 (Matsuura et al., 2014), 2 
(Chang et al., 2011) and 3 (Jin et al., 2013).  Preclinical experiments demonstrated that MSC 
transplantation could alleviate motor function deterioration in SCAs. In a recent study, the 
authors observed an improvement in rotarod performance and neuroprotective effects on 
cerebellar Purkinje cells in hBM-MSC transplanted SCA2 transgenic mice. In this study, they 
compared intracranial (IC) and IV transplantation of hBM-MSC and concluded that IV was 
more effective than IC transplantation, as IC treatment did not demonstrate improvements 
in the rotarod performance (Chang et al., 2011). Moreover, in another study where the 
authors used SCA1 transgenic mice, intrathecal injection of mouse BM-MSC suppressed the 
disorganization of the Purkinje cell layer and the atrophy of dendritic arborization, and 
treated mice presented better performances in rotarod than non-treated mice, reaching 
similar performances to wild type animals, which reveals a great improvement in motor 
coordination (Matsuura et al., 2014).  
In another report, Edalatmanesh and col. transplanted rat BM-MSC into Wistar rats after 
performing a unilateral lesion in the cerebellum with quinolinic acid, which affects memory 
and motor coordination. It was shown that MSC could alleviate the cerebellar dysfunction, 
decreasing the functional deficits as well as the neuronal loss in the injured area 
(Edalatmanesh et al., 2011). Additionally, Jones et al. also reported the positive effects of 
MSC transplantation in cerebellar ataxias. The authors demonstrated that BM-MSC cells 
were capable of integrating into the cerebellar tissue, and could support survival of Purkinje 
cells, and ultimately improve the motor functions of mutant mice, evaluated by rotarod 
performances (Jones et al., 2010). In another study, the authors used hMSC isolated from 
neonatal umbilical cord and transplanted them into a model of ataxic mice induced by 
cytosine beta-Darabinofuranoside (Ara-C). Zhang et al. showed that MSC can alleviate 
motor impairments and cerebellar atrophy, since treated mice presented better 
performances in rotarod and open field tests than non-treated mice; additionally animals 
exhibited increments on both body weight and cerebellar volume, and proliferation of 
Purkinje cells and internal granular layer cells (Zhang et al., 2011).  
To further support MSC therapeutic potential, several either completed or ongoing 
clinical trials have been using MSC for neurological disease therapies. According to the EU 
Clinical Trials Register, there are only 2 clinical trials using MSC presently ongoing in the 
European Union (EU) or/and the European Economic Area (EEA): 1 for multiple sclerosis, and 
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another for amyotrophic lateral sclerosis, and there is no registry of clinical trials in 
cerebellar ataxias (www.clinicaltrialsregister.eu). Nonetheless, in others parts of the world 
(namely in Taiwan, India and China) a few clinical trials have been evaluating the therapeutic 
potential of MSC in some SCAs, including MJD/SCA3 (www.clinicaltrials.gov; ClinicalTrials.gov 
Identifiers: NCT01489267, NCT01958177, NCT01360164, NCT01649687). 
In the General Hospital of the Air Force (Beijing, China) the safety and effectiveness of 
umbilical cord MSC (UC-MSC) intrathecal transplantation in patients with SCA and multiple 
system atrophy-cerebellar type C (MSA-C) was evaluated. The study recruited a total of 24 
patients, 10 diagnosed with MSA-C and 14 with SCA, and they were injected with both UC-
MSC and dexamethasone intrathecally weekly, for 4 consecutive weeks (all patients received 
1 course of treatment, except 3 who received 2). In this trial it was demonstrated that 
patients’ symptoms, including unstable walking and standing, slow movement, fine motor 
disorders of the upper limbs, writing difficulties and dysarthria were improved, and the 
scores of International Cooperative Ataxia Rating Scale (ICARS) and Activity of Daily Living 
Scale (Haacke et al.) were decreased 1 month after the treatment. However, non-treated 
patient were not included in this study. This treatment did not report serious side effects, 
besides dizziness after the lumbar puncture, lumbago, and headache, which disappeared 1 – 3 
days after MSC delivery without any special treatment (Dongmei et al., 2011).   
Likewise, Jin et al. reported a study that assessed the efficacy and potential toxicity of 
human umbilical cord MSC (hUC-MSC) therapy in patients genetically diagnosed with SCA1, 
SCA2, or SCA3 (ClinicalTrials.gov Identifier: NCT01360164). Sixteen patients receiving 4 
UC-MSC treatments at 1week intervals were included. The first treatment consisted only on 
the IV injection of UC-MSC (4x107 cells), whereas the other 3 treatments included IV (2x107 
cells) and intrathecal (2x107 cells) injection of UC-MSC. The majority of patients (63%) 
showed significant improvements on the Berg balance scale (BBS) scores (used to evaluate 
the balance of patients) from baseline, at 3 and 6 month after UC-MSC treatment. Similar 
results were obtained with ICARS, where patients presented amelioration of neural function 
at the third and sixth months after the treatment. Regarding side effects, no serious 
transplant-related adverse events were reported in 12 months of follow-up. This study 
suggested that UC-MSC transplantation is safe and might delay the progression of SCA (Jin et 
al., 2013).  
As conclusion, MSC have been proving to be a very promising therapy in SCAs. 
However, for most of the SCAs, and particularly in MJD, pre-clinical studies evaluating the 
potential of MSC are lacking. Furthermore, studies in human patients do not allow assessing 
for direct neuropathology evaluation prior and after MSC delivery. As such, it would be 
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crucial to study MSC cellular therapy in MJD models prior to its use in the clinics. In the 
present study, a MJD transgenic mouse model was used to investigate whether MSC can 
alleviate both motor behaviour and neurodegeneration in this fatal disorder. 
Thereby, the main aim of our study was to investigate the in vivo therapeutic relevance of 
MSC for MJD therapy. Similarly to what it has been shown in other SCAs, we expect to 
provide evidences that MSC can become a valuable therapy for MJD.
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Objectives 
 
The main aim of the present work was to investigate the in vivo therapeutic potential of 
MSC for MJD therapy. For that, the specific aims were as follows: 
 
- isolate and characterize a population of mouse MSC prior to transplantation; 
- analyse whether MSC can engraft when injected stereotaxically in the cerebellum 
of a MJD transgenic mouse model (Torashima et al., 2008); 
- investigate whether MSC can alleviate MJD motor behaviour in MJD transgenic 
mice; 
- evaluate whether MSC transplantation can rescue the neuropathology in MJD 
transgenic mice. 
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Abstract 
 
Machado Joseph disease or Spinocerebellar ataxia type 3 is the most common SCA 
worldwide, caused by an expanded CAG repeat in the MJD1 gene, which translates into a 
polyQ tract within the ataxin-3 protein. Currently, there is no therapy able to modify or 
delay disease progression. Multipotent mesenchymal stromal cells (MSC) are extremely 
promising tools for therapy of neurodegenerative disorders and, more recently, this 
therapeutic approach became motif of interest with respect to cerebellar disorders, such as 
spinocerebellar ataxias (SCAs). 
In the present study, we investigated whether the stereotaxic transplantation of MSC 
into the cerebellum of MJD transgenic mice can produce a neuroprotective effect, allowing 
rescue of the extremely severe phenotype of this mouse model. We found that MSC could 
engraft in the cerebellum and mediate a significant improvement of motor coordination. 
Furthermore, MSC alleviated the neuropathology of transgenic MJD mice, preserving the 
Purkinje cells and both molecular and granular layers. Therefore, our results suggest that 
MSC can become a strong candidate for disease-modifying MJD therapies, so far inexistent. 
 
 
 
 
Keywords: Spinocerebellar ataxia type 3; Machado Joseph disease; Multipotent 
mesenchymal stromal cells; transplantation; MJD transgenic mice. 
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1. Introduction 
Machado Joseph disease (MJD), also known as Spinocerebellar ataxia type 3 (SCA3), is an 
autosomal dominant neurodegenerative disorder reported as the most common SCA 
worldwide (Bettencourt and Lima, 2011). This disorder is caused by the over repetition of 
the CAGn trinucleotide in MJD1 gene, translating into an expanded polyQ tract in the 
ataxin-3 protein. As result, ataxin-3 acquires an abnormal conformation with more 
propensity to aggregate, which triggers a degenerative process and accumulates forming 
neuronal intranuclear inclusions (Nóbrega and de, 2012, Paulson et al., 1997b). 
Neuropathologically, not only the cerebellum is affected, but also other regions such as the 
substantia nigra, brainstem and the striatum. The clinical hallmark of MJD is the progressive 
gait and limb ataxia (Nóbrega and de, 2012). 
Despite recent progresses regarding MJD putative therapies (Alves et al., 2010, 
Nascimento-Ferreira et al., 2013, Nóbrega et al., 2013, Simões et al., 2014), there is no 
effective therapy for MJD patients. Nonetheless, MSC have been reported as a promising 
therapy for several neurodegenerative disorders, including multiple sclerosis, amyotrophic 
lateral sclerosis, Parkinson’s disease, Alzheimer’s disease and HD (Trzaska et al., 2008). 
Furthermore, MSC have already been used in ataxias either in pre-clinical and clinical studies 
and there is some evidence that this approach can become an effective therapy for SCAs 
(Chang et al., 2011, Dongmei et al., 2011, Jin et al., 2013, Matsuura et al., 2014). It has been 
also demonstrated that MSC are safe, as they are considered to be non-tumorigenic and 
have low immunogenicity, allowing both for autologous and allogeneic transplants 
(Parekkadan and Milwid, 2010, Sadan et al., 2009). 
MSC are multipotent adult stem cells with fibroblast-like appearance that can self-renew 
and differentiate into mesenchymal lineage cells, such as osteoblasts, adipocytes, 
chondrocytes and myocytes (Caplan, 1991, Friedenstein et al., 1970). They are easily isolated 
from several tissues, namely from the bone marrow where they play an important function 
in the haematopoiesis support (Parekkadan and Milwid, 2010). Besides that, they exhibit 
unique therapeutic characteristics. They can “sense” the environment created by the 
“signals” emitted by the injured tissues and/or immune cells and then home to the lesion 
sites, where they secrete growth factors, ILs or cytokines, and extracellular matrix proteins 
thus exerting immunomodulatory and protective effects to promote the functional recovery 
of injury and/or inflammation (Salem and Thiemermann, 2010). 
The evidence reported in the literature suggests that MSC could be an efficient approach 
for the correction of SCAs, particularly for MJD. Therefore, in this study we aimed at 
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evaluating whether MSC transplantation would alleviate the phenotype in MJD transgenic 
mice model and would improve the MJD associated neuropathology. 
 
 
2. Materials and methods 
 
2.1. MSC isolation and expansion 
MSC were isolated from bone marrow of 6- to 8- weeks-old wild type mice with 
C57BL/6 background of both genders. For isolation, femurs and tibias were collected and 
transferred to culture medium Dulbecco's Modified Eagle Medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS, Invitrogen), 100U/ml penicillin and 100µg/ml streptomycin 
(Invitrogen) in a sterile petri dish. Then, the contents of marrow was flushed with medium 
and collected into a sterile petri dish. The cell suspension was homogenized with a 20G 
syringe, centrifuged and the pellet resuspended in DMEM (not supplemented). Finally, 
mononuclear cells were separated in a Ficoll (Sigma) density gradient and resuspended in 
DMEM/F12 (Gibco) supplemented with 10% FBS, 100U/ml penicillin and 100µg/ml 
streptomycin (Gibco), 20 ng/ml epidermal growth factor (EGF, PeproTech), 20 ng/ml 
fibroblast growth factor (FGF, PeproTech) and 2% B-27 (Gibco) and were incubated at 37°C 
in 5% CO2/air atmosphere (Fig. S1-a). Forty-eigth hours later, nonadherent cells were 
removed and adherent cells were expanded for approximately 2-3 weeks, with medium 
changes every 2-3 days, until sub-confluence was reached. To eliminate hematopoietic 
contaminants in MSC cultures (Javazon et al., 2004, Phinney et al., 1999), the elimination of 
the CD45+ cells was performed by cell sorting (Fig. S1-b). MSC were expanded in the 
conditioned medium described above and frozen in FBS with 10% DMSO for later usage. 
 
2.2. Flow cytometry  
MSC were displaced by trypsinization, passed through a 70 µm filter (BD Falcon) and 
single cell suspension was incubated in 3% bovine serum albumin (BSA) for 15 min at 4ºC to 
block non-specific binding of the primary antibody and labelled with specific antibodies 
(eBioscience) for 30 min at room temperature (RT) in the dark to analyse the expression of 
the following markers: fluorescein isothiocyanate (FITC) conjugated anti- mouse CD45 and 
anti-mouse CD106 (VCAM-1), phycoerythrin (PE) conjugated anti-mouse CD105 (endoglin), 
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anti-mouse/rat CD29 (integrin beta 1, Iß-1), anti-mouse CD73, and PE-Cy7 conjugated anti-
mouse Ly-6A/E (Sca-1). For every condition, the appropriate isotype control antibodies 
(eBioscience) were used as negative controls. Moreover, every marker were analysed either 
alone or in double staining protocols (using 2 markers with different conjugated antibodies) 
in order to exclude acquisition of non-specific staining. Acquisition was done in a FacsCalibur 
flow cytometer (Becton Dickinson). Data was analysed with Cell Quest software (BD) and 
gating included single cells on the basis of forward and side light-scatter parameters (FSC vs. 
SSC); log fluorescence was collected and displayed as single parameter histograms. 
 
2.3. Immunocytochemical procedure  
MSC were washed with phosphate buffer solution (PBS, 0.1M) and fixed with 4% 
paraformaldehyde (PFA, Sigma). Afterwards, cells were permeabilized with 1% Triton X-100 
(Sigma) followed by 1 hour blocking with 10% normal goat serum (NGS, Sigma) and 
overnight incubation with the primary antibodies at 4ºC. The following primary antibodies 
were used: mouse anti-β tubulin III, (1:500, Invitrogen), mouse anti-MAP2 (microtubule-
associated protein 2, 1:250 Sigma)g, rabbit anti-nestin (1:500 Millipore), rabbit anti-GFAP 
(glial fibrillary acidic protein, 1:500 Dako), rabbit anti-Iba1 (ionized calcium-binding adapter 
molecule 1, 1:500 Dako), rabbit anti-Nanog (1:400 Cell Signalling) and mouse anti-SSEA4 
(stage-specific embryonic antigen-4, 1:500 Invitrogen). Subsequently, the incubation with the 
secondary antibodies was performed for 2 h at RT. The secondary antibodies used were as 
follows: goat anti-rabbit and/or mouse conjugated alexa 488 or alexa 594 (1:200 Invitrogen). 
Nuclei were stained with 4, 6-diamidino-2-phenylindoline, DAPI (1:5000, Applichem). 
Fluorescence images were acquired with a Zeiss Axiovert 200 imaging microscope. 
 
2.4. MSC infection with lentivirus encoding for GFP 
The lentivirus vector encoding for GFP (green fluorescent protein) was produced in 
293T cells using a four-plasmid system as previously described (Alves et al., 2008).  The 
lentiviral particles were resuspended in 0.5% BSA in PBS and the viral particle content of 
batches was determined by measuring human immunodeficiency virus 1 (HIV-1) p24 antigen 
levels (RETROtek). Viral stocks were stored at -80°C until use. 
MSC with eleven passages were displaced by trypsinization and 200,000 cells were plated 
in 6 multiwell plates. Twenty-four hours later, lentivirus encoding for GFP were added to 
cells (80ng of virus/100,000 cells) and 4 µl/ml of hexadimethrin bromid (Sigma). Cells were 
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incubated at 37°C in 5% CO2/air atmosphere overnight and then lentivirus were removed 
by replacing the culture medium. Eight days after infection, MSC were assessed for GFP 
expression with widefield fluorescence microscopy with a Zeiss Axiovert 200 imaging 
microscope and 12 days later the percentage of MSC infected with GFP were determined by 
analysing in a FacsCalibur flow cytometer (Becton Dickinson). Data were then analysed by 
Cell Quest software (BD). 
 
2.5. In vivo experiments 
 
2.5.1. Transgenic mouse model 
A MJD transgenic mouse model (C57BL/6 background) expressing the N-terminal-
truncated human ataxin-3 with 69 glutamine repeats together with an N-terminal 
hemagglutinin (HA) epitope in cerebellar Purkinje cell, driven by the L7 promoter was used 
(Oue et al., 2009, Torashima et al., 2008) (Fig. S2-a), and maintained in the animal house 
facility of the Centre for Neuroscience and Cell Biology (CNC) of the University of Coimbra 
by backcrossing heterozygous males with C57BL/6 females (Nascimento-Ferreira et al., 
2013). The animals were housed in a temperature-controlled room and maintained on a 12 h 
light/dark cycle. Food and water were available ad libitum. The experiments were carried out 
in accordance with the European Community Council Directive (86/609/EEC) for the care 
and use of laboratory animals. Genotype was confirmed by PCR.   
The present study used 2 groups of animals: MSC-treated mice (stereotaxically 
transplanted with MSC, n=12), and the non-treated mice or control group (without 
injection, n=11). The 2 referred groups included animals of both genders. 
 
2.5.2.  Stereotaxic surgery 
Mice were transplanted with 3-5 weeks of age and animals with the same age were used 
as controls (Fig S2-b). After anaesthesia of the mice by intraperitonial injection of a mixture 
of ketamine (100mg/kg, Clorketam 1000, Vétaquinol) with xylazine (10mg/kg, Rompun®, 
Bayer), the treated group was transplanted with a single injection of 300,000 MSC (300,000 
cells/3µl HBSS) injected into the cerebellum at the following coordinates: -1.8 mm rostral to 
lambda, 0 mm midline, and 1.8 to 2.2 mm ventral to the skull surface, with the mouth bar set 
at -3.3 (Fig. S2-c). The cells were injected at a rate of 0.25 ml/min through an automatic 
injector (Stoelting Co.). 
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2.5.3. Behavioural assessment  
Mice were subjected to motor tests every 2 weeks until 12 weeks after transplant (Fig. 
S2-b). All tests were performed after acclimatization. For each time point, to evaluate 
statistical significance unpaired student’s t-test was performed in GraphPad software (La 
Jolla), and Welch's correction was performed when variances were significantly different. 
Data are represented as mean±SEM. 
 
2.5.3.1. Rotarod 
Fore and hind limb motor coordination as well as balance were evaluated in a rotarod 
apparatus (Letica Scientific Instruments). Mice were placed on the rotarod at a constant 
speed (5rpm), or at accelerated speed (from 4 to 40rpm in 5 minutes) for a maximum of 5 
minutes, and the latency to fall (the amount of time they could stand in the rotated wheel) 
was recorded. Mice were subjected to 4 trials for each test at each time point, with a 
minimum of 15 minutes rest between trials. For statistical analysis, the mean latency to fall 
off the rotarod of 3 trials was used (the trial with the most distant value from the average 
was eliminated). 
 
2.5.3.2. Swimming 
Coordination of limbs used during voluntary locomotion was assessed by the swimming 
test. Mice were placed on one extremity of a tank filled with water at RT and allowed 
swimming along a 60-cm-long, 14-cm-wide tank until they achieve the platform (located at 
the other extremity and with the water level at the platform level, Fig. S2-d). The latency to 
navigate along the tank (time between they were dropped in the water and they reached the 
platform) was recorded. Mice were subjected to 4 trials for each test at each 3 point, with a 
minimum of 15 minutes rest between trials. For statistical analysis, the mean latency of 3 
trials was used (the trial with the most distant value from the average was eliminated). 
 
 
2.5.3.3. Footprint 
Gait analysis was performed by the footprint test. Hind- and forefeet were coated with 
black and white nontoxic paints respectively, and the animals were allowed to walk along a 
100-cm-long, 10-cm-wide runaway (with 15-cm high walls) over a fresh sheet of green paper. 
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The footprint patterns were analysed for hind base width, which was measured as the 
distance between the left and right hind footprints. These values were determined by 
measuring the perpendicular distance of a given step to a line connecting its opposite 
preceding and proceeding steps (Fig. S2-e). Six consecutive steps were used for evaluation 
(to perform 5 measurements), excluding the footprints at the beginning and end of the run. 
For statistical analysis, the mean of 4 measurements was used (eliminating the trial with the 
most distant value of the average).  
 
2.6. Histological processing 
 
2.6.1. Tissue preparation 
Twelve weeks post MSC transplantation, animals were intracardiacally perfused with PBS 
followed by fixation with 4% PFA (Fig. S3-a). The brains were removed and post-fixed in 4% 
PFA for 24 h at 4ºC. After a cryoprotective incubation in 20% sucrose/PBS for 48 h at 4ºC, 
brains were frozen at -80ºC and 35µm sagittal sections were cut at a cryostat-microtome 
(Leica CM3050S, Leica Microsystems). Sections of the entire cerebellum were collected and 
stored in 48-well plates as free-floating sections in PBS/0.05 µM sodium azide at 4ºC. 
 
2.6.2. Engraftment evaluation 
To evaluate MSC engraftment, sections of one column of the 48-well plates were used. 
Sections of transplanted mice were mounted in gelatinized slides and were submitted to a 30 
min dehydration period at 37ºC, followed by 15min hydration in PBS. Nuclei staining was 
performed with DAPI incubation for 10 min. After drying, sections were mounted in Mowiol 
reagent (Sigma). Fluorescence images were acquired with a Zeiss Axiovert 200 imaging 
microscope. 
 
2.6.3. Neuropathological evaluation 
 
2.6.3.1. Immunohistochemical procedure 
The immunohistochemical procedure was performed in a free-floating system, as 
referred elsewhere (Simões et al., 2014). Briefly, sections were simultaneously blocked and 
permeabilized with 0.3 % Triton X-100 in PBS supplemented with 10 % NGS  for 1 h at RT. 
33 
Sections were incubated overnight at 4ºC with the following primary antibodies diluted in 
0.3% triton/PBS supplemented with 10% NGS: rabbit anti-calbindin D-48K (1:1000 Millipore) 
and mouse anti-HA (1:1000 InvivoGen). After the incubation with the primary antibody, 
sections were incubated with the appropriate secondary antibodies: goat anti-rabbit or goat 
anti-mouse conjugated to alexa 594 (1:200 Invitrogen) for 2 h at RT. Afterwards, sections 
were incubated with DAPI for 10 min to perform the nuclei staining and then mounted in 
gelatinized slides. Once dried, slides were mounted in Mowiol reagent (Sigma). Fluorescence 
images were acquired with a Zeiss Axiovert 200 imaging microscope (Fig. S3-b). 
 
2.6.3.2.   Cresyl violet staining to determine cerebellar layer thicknesses 
Cerebellar sections were mounted in gelatinized slides and stained with cresyl violet for 
2 minutes, differentiated in 70% ethanol, dehydrated by passing twice through 95% ethanol, 
100% ethanol and xylene solutions, and mounted with EukittH (Sigma) (Fig. S3-c). 
 
2.7. In vivo imaging quantification 
For all in vivo quantifications, we have addressed for sections nearby the localization of 
MSC grafts. 
 
2.7.1. Quantification of granular and molecular layers thicknesses 
To assess for the granular and the molecular layer thicknesses, quantifications were 
performed in 4 sections per animal, with an inter-section distance of 280 µm. In the control 
group the same localization on the 48-well plate used for treated mice was selected. The 
molecular layer size was determined by measuring the width of this layer (the Purkinje cell 
layer was also included); the width of the granular layer was assessed excluding the Purkinje 
cells. Measurements were all made in between lobules, in order to use precisely defined 
regions. Results were converted to µm using the Image J software. 
 
2.7.2. Quantification of Purkinje cells and mutant ataxin-3 aggregates 
The quantification of Purkinje cells was performed in the lobules II and III using 4 sections 
per animal (inter-section distance: 280 µm). The areas were scanned with a Zeiss PALM 
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Axiovert 200M microscope. To determine the number of Purkinje cells, we accounted for 
the cells immunoreactive for HA, as in our model, these cells have an N-terminal HA 
epitope (Torashima et al., 2008). Additionally, optical densitometry of immunoreactivity for 
calbindin was also used to assess for Purkinje cell quantification (Nascimento-Ferreira et al., 
2013). Outliers were determined by average ± standard deviation and were excluded.  The 
evaluation of the HA aggregates was performed in the whole cerebellum using 6 sections per 
animal, with an inter-section distance of 280 µm (also scanned with Zeiss PALM Axiovert 
200M microscope). For all the quantifications, the image J acquisition and analysis software 
was used. 
 
3. Results 
 
3.1.  The isolation method of BM-MSC generates a relatively pure MSC 
population and MSC express neuronal markers prior to 
transplantation 
Given MSC heterogeneity and their likely contamination by hematopoietic cells 
(Javazon et al., 2004, Phinney et al., 1999), we performed MSC characterization to evaluate 
the purity of MSC population. For that, MSC were characterized by flow cytometry for 
characteristic MSC markers and by immunocytochemistry for neuronal/glial marker 
expression (Fig.1). In culture, MSC exhibited fibroblast-like morphology and grew as a 
monolayer, both typical features of MSC (Fig.1-a). Furthermore, MSC were negative for the 
hematopoietic markers CD11b and CD45 and highly positive (between 95%-100%) for the 
mesenchymal markers CD73, CD105, Sca-1, CD29 and CD106 (Fig.1-b). As such, a relative 
pure population of MSC can be obtained by our isolation/selection method. 
Additionally, we could observe that in vitro MSC expressed both neuronal and glial 
markers (Fig.1-c), including nestin (a marker for immature neurons), β-tubulin III and MAP2 
(markers for mature neurons), GFAP and Iba-1 (markers for astrocytes and microglia, 
respectively). MSC did also express Nanog and SSEA-4, two markers for pluripotency (Fig.1-
c-panel D).  
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Figure 1 - MSC characterization. a) Brightfield photomicrograph showing that MSC exhibit a fibroblast-like 
morphology and grow in a monolayer in vitro cultures. b) Phenotypic characterization of MSC performed by 
flow cytometry demonstrating that MSC are negative for the hematopoietic markers CD11b and CD45 and 
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highly express the following markers: CD73, CD105, Sca-1, C29 and CD106. c) Immunocytochemistry reveals 
that in vitro MSC express markers for both immature (nestin, in red: arrows panel C) and mature neurons 
(Tubulin III, in green: arrows panel A; MAP2, in green: arrows panels B and C), astrocytes (GFAP, in red: 
arrowhead panel A), and microglia (Iba-1, in red: arrow, panel B). MSC did also express Nanog or SSEA-4, two 
markers for pluripotency (Nanog in green and SSEA4, in red: arrows, panel D). Abbreviations: GFAP, glial 
fibrillary acidic protein; Iba-1, ionized calcium-binding adaptor molecule 1; MAP-2, microtubule-associated 
protein 2; MSC, multipotent mesenchymal stromal cells; Sca-1, stem cells antigen 1; SSEA-4, stage-specific 
embryonic antigen-4. 
 
3.2. MSC are GFP-positive prior to transplantation and are able to 
engraft when injected stereotaxically in the cerebellum 
In order to follow the cells after transplantation in the cerebellum of MJD transgenic 
mice, MSC were previously infected with lentiviral vectors enconding for GFP (Fig.2-a). To 
evaluate the efficacy of infection, flow cytometry analysis was performed on gated live cells. 
We could observe that a highly efficient infection (88% of cells expressing GFP – Fig2-b) was 
obtained, suggesting that this is an effective method to track MSC in vivo. 
GFP-labelled MSC were stereotaxically injected in the cerebellum of transgenic mice. To 
investigate cells engraftment, animals were sacrificed at intermediate intervals and GFP signal 
was checked on sagittal brain sections of transplanted mice. We could detect MSC at 2 
(n=1), 5 (n=1), 9 (n=3) - data not shown - and 12 weeks after transplantation (n=5) (Fig. 2-
c). At 12 weeks post-transplantation MSC were mostly detected near the second or the 
third lobules of the cerebellum (Fig. 2-d). We can then conclude that MSC integrated into 
the cerebellar tissue and survive for an extensive period of time. 
 
Figure 2 - GFP-labeled MSC can engraft within the cerebellum. a) Fluorescence microscopy and b) 
flow cytometry analysis, showing that MSC were robustly infected with a lentivirus encoding for GFP. Flow 
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cytometry analysis was performed on gated live cells. MSC were efficiently infected with GFP (88% of gated 
cells) c) Photomicrograph showing that GFP+-MSC could engraft in the cerebellum as they were detected at 12 
weeks after transplant. (GFP+-MSC - green; DAPI - blue). d) Schematic representation of MSC localization in 
the cerebellum of transgenic mice at 12 weeks after transplant. Abbreviations: DAPI, 4, 6-diamidino-2-
phenylindoline; GFP, green fluorescent protein; MSC, multipotent mesenchymal stromal cells. 
 
3.3. MSC promote phenotype alleviation in MJD transgenic mice 
To assess the therapeutic potential of MSC in promoting the functional recovery or 
phenotype improvement in MJD, motor behaviour was evaluated in transplanted MJD 
transgenic mice. As controls, non-treated (non-injected) MJD mice of the same age were 
used. Behavioural tests - constant and accelerated rotarod, swimming and footprint - were 
performed every 2 weeks after transplantation, to permit assessing the functional recovery 
of MJD mice over time. 
Balance and motor coordination deficits were evaluated by constant and accelerated 
rotarod, as well as by the swimming test. At 4 weeks after transplantation, MSC mediated 
improvement of the performance of treated mice, presenting significant better performances 
when comparing to non-treated mice in both constant (NTMJD 4.038 ± 0.9347 sec vs 
MJD+MSC 10.45 ± 2.042 sec, p=0.012; Fig.3-a) and accelerated rotarod (NTMJD 7.499 ± 
1.677 sec vs MJD+MSC 14.65 ± 2.869 sec, p=0.048; Fig.3-b), which measures the latency to 
fall.  In swimming test, mice were placed at one extremity of a recipient filled with water and 
the time between they were dropped in the water and they reached the platform was 
registered. At the same time-point (4 weeks after the treatment), MSC transplantation 
significantly improved the performance of treated animals, reaching the plataform in less time 
as compared to non-treated mice (NTMJD 6.333 ± 0.6592 sec vs MJD+MSC 4.445 ± 0.3371 
sec, p=0.016; Fig.3-c). 
Additionally, the footprint test was used to evaluate the progression of gait and limb 
ataxia. We measured the distance between the left and the right hind footprint (hind base 
width). In our model, this distance is larger in MJD mice relatively to wild type mice, as a 
result of balance defects. Though not significant, MSC-treated mice showed a tendency to 
decrease in the hind base width, when compared to non-treated mice at 4 weeks after 
transplants (Fig.3-d; NTMJD 2.997 ± 0.07997cm vs MJD+MSC 2.768 ± 0.08569cm, p=0.065), 
suggesting that, in accordance to our previous results, MSC transplantation is mediating a 
tendency for improvement in this test as well. 
Overall, a phenotypic alleviation was observed at 4 weeks after transplant. At later 
time points, MSC effect was not able to revert MJD phenotype. This may be explained by the 
fact that MSC transplantation has been performed at a late time point (3 to 5 weeks of age), 
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point at which the disease is already very severe in this transgenic mice model, showing 
dramatic motor impairments when compared to wild-type mice, as already demonstrated by 
our group (Nascimento-Ferreira et al., 2013).  
 
 
Figure 3 - Analysis of behaviour performance of MSC-treated and non-treated MJD transgenic 
mice. Mice were placed on the rotarod at a) a constant speed (5rpm, throughout 5 min) or b) accelerated 
speed (4 to 40rpm in 5 min), and their latency to fall was measured. Treated mice with MSC have shown 
significant better performances in both constant and accelerated rotarod when compared to non-treated mice, 
at 4 weeks after transplantation. c) Swimming test performance at 4 weeks after MSC transplantation, showing 
that treated animals significantly improved their performance comparatively to non-treated mice. d) Hind base 
quantitative analysis (footprint test) performed at 4 weeks after transplant. MSC-treated mice showed a 
tendency to decrease (non-statistical) on hind base width when compared to non-treated mice. Values are 
presented as mean ± SEM (Unpaired Student’s test with Welch’s correction when variances were significantly 
different, ***p <0.001,**p <0.01 and *p <0.05). Non-treated mice (NTMJD, n=11) and treated mice 
(MJD+MSC, n=12). Abbreviations: MJD, Machado Joseph disease; MSC, multipotent mesenchymal stromal 
cells. 
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3.4. MSC transplantation promotes neuropathological improvements in 
MJD transgenic mice 
To evaluate whether MSC transplantation can mitigate the neuropathology associated 
with MJD motor function impairments, we analysed both the molecular and granular layer 
thicknesses, the number of mutant ataxin-3 aggregates and both the Purkinje cell number 
and immunoreactivity for the calbindin protein (a marker for Purkinje cells) by optical 
densitometry. All brain sections were examined at 12 weeks after transplant around the area 
where MSC were found. 
The thickness of the cellular layers showed a tendency to increase in treated animals 
(Fig.4-a) when compared to non-treated controls, meaning that mice transplanted with MSC 
revealed a conservation of the molecular layer thickness, since these mice presented a 
significant thicker molecular layer than non-treated mice between lobules II and III 
(NTMJD=101.2 ± 2.029µm vs MJD+MSC=124.1 ± 5.135µm, p=0.0061), and between lobules 
III and IV (NTMJD=106.0 ± 6.306µm vs MJD+MSC=142.0 ± 10.93µm, p=0.0061; Fig.4–b). 
Regarding the granular layer, we also observed a tendency to increase the thickness of the 
layer between lobules III and IV in MSC treated mice relatively to non-treated animals 
though not reaching statistical significance (NTMJD= 59.07 ± 1.479µm vs MJD+MSC= 68.09 
± 3.568µm, p=0.0582; Fig.4-b).  
Furthermore, since transgenic mice present marked defects in the Purkinje cells, we 
performed immunostaining for calbindin to assess for the immunoreactivity against this 
marker (Fig.4-c). Treated mice presented a significant increase of the optical densitometry of 
calbindin immunoreactivity when compared with non-treated mice in lobule II 
(NTMJD=22.56 ± 0.3592 a.u. vs MJD+MSC=26.23 ± 1.050 a.u., p=0.0349) and III 
(NTMJD=23.41 ± 0.3093 a.u. vs MJD+MSC=25.60 ± 0.5813 a.u., p=0.0311; Fig.4-d). 
Moreover, we measured the number of Purkinje cells by immunostaining for HA (Fig.4-e) as 
in our model these cells express mutant ataxin-3 tagged by an N-terminal HA epitope. 
Treated mice exhibited a non-significant tendency for increase in the Purkinje cell number 
(lobule II: NTMJD=78.67 ± 12.33 cells vs MJD+MSC=99.67 ± 4.485 cells, p=0.1848; and 
lobule III: NTMJD=58.00 ± 23.46 cells vs MJD+MSC=108.3 ± 10.73 cells, p=0.1451; Fig.4-f). 
As in this model Purkinje cells present aggregates of mutant ataxin-3, we measured the 
number of aggregates present in the whole cerebellum. However, no significant differences 
were detected between treated and non-treated mice (NTMJD=12.55 ± 2.359 aggregates vs 
MJD+MSC=11.88 ± 1.808 aggregates, p=0.8279; Fig.4-f). 
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Overall, MSC transplantation promoted the recovery of cerebellar atrophy and the 
survival of Purkinje cells, leading to neuropathological improvements.  
 
 
Figure 4 - Neuropathology of the cerebellum of MJD transgenic mice is protect by the MSC 
transplantation. a) Representative photomicrographs of sagittal sections of the cerebellum of both non-
treated (upper panel) and treated (lower panel) MJD transgenic mice stained with cresyl violet, showing the 
molecular (ML) and granular layers (GL). b) Quantification of both molecular and granular layer thicknesses. A 
significant increase in the molecular layer thickness was observed in MJD transgenic mice treated with MSC 
between lobules II and III (NTMJD, n=4; MJD+MSC, n=4; p=0.006), and between lobules III and IV (NTMJD, 
n=5; MJD+MSC, n=5; p=0.02), when comparing with non-treated mice. Treated animals presented a tendency 
for increase in the granular layer thickness between lobules III and IV (NTMJD, n=4; MJD+MSC, n=4; p=0.058). 
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c) Representative photomicrographs of sagittal sections of the cerebellum of both non-treated (left panels) and 
treated (right panels) MJD transgenic mice immunostained with anti-calbindin. d) Quantification of optical 
densitometry of calbindin immunoreactivity. MSC transplantation significantly increased calbindin 
immunoreactivity in lobule II and III as compared to controls (NTMJD, n=3; MJD+MSC, n=4; p=0.03). e) 
Representative photomicrographs of sagittal sections of the cerebellum of both non-treated (left panels) and 
treated (right panels) MJD transgenic mice immunostained with anti-HA. f) Quantification of both Purkinje cell 
and aggregates (arrow) number in both treated and non-treated groups. A tendency to increase the Purkinje 
cells number was detected in the MSC-treated relatively to non-treated MJD transgenic mice (lobule II: 
NTMJD, n=3; MJD+MSC, n=3; p=0.18 and lobule III: NTMJD, n=4; MJD+MSC, n=3; p=0.15). There was no 
significant difference in aggregates number between treated and non-treated group (NTMJD, n=4; MJD+MSC, 
n=4; p=0.83). Values are presented as mean ± SEM (Unpaired Student’s t-test, ***p <0.001, **p <0.01 and *p 
<0.05). Abbreviations: a.u., arbitrary units; GL, granular layer; HA, hemagglutinin; MJD, Machado Joseph 
disease; MJD+MSC, treated mice; ML, molecular layer; MSC, multipotent mesenchymal stromal cells; NTMJD, 
non-treated mice. 
 
 
4. Discussion 
 In this work we investigated whether MSC transplantation in the cerebellum could 
alleviate the phenotype of MJD transgenic mice. Transplanted MSC engrafted in the 
cerebellum and rescued motor impairments and cerebellar neuropathology in this mouse 
model for MJD.  
 MSC-based therapies are promising therapies for neurodegenerative diseases, since it 
has been reported that they are capable to promote protection, tissue regeneration and/or 
modulation of the immune system in animal models for a number of neurological disorders 
(Trzaska et al., 2008). More recently, this therapeutic approach has received considerable 
interest with respect to cerebellar disorders, such as SCAs. Chang and collaborators have 
shown that IV delivery of MSC can promote recovery in mice motor function as well as 
delay the disease onset in a transgenic mouse model of SCA-2 by rescuing cerebellar 
Purkinje cells (Chang et al., 2011). Another group has shown that MSC treatment improved 
the morphology of the cerebellum and improved the motor behaviour when intrathecally 
injected in a transgenic mouse model of SCA-1 (Matsuura et al., 2014). 
 Aligned with these results, clinical trials with MSC are already running and there have 
been reports that MSC are safe and may delay disease progression in some SCAs (Dongmei 
et al., 2011, Jin et al., 2013), including MJD (www.clinicaltrials.gov: ClinicalTrials.gov Identifiers 
- NCT01489267, NCT01360164). Nevertheless, clinical trials only allow evaluating the 
phenotype whereas the direct neuropathology evaluation prior and after MSC 
transplantation is not possible to perform in human patients. Moreover, how MSC mediate 
these effects remains a matter of controversy and to this contributes the lack of studies 
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evaluating MSC effect in animal models. In fact, studies in animal models are crucial to 
understand the pathways through which these cells mediate therapeutic effects, adjust 
delivery routes and frequency of intervention and anticipate safety issues. In this work, we 
show that MSC transplantation in the cerebellum of the MJD transgenic mouse model 
alleviates motor impairments and its associated neuropathology, providing evidences that 
MSC can become a therapy for MJD. Importantly this experimental model is expected to 
contribute to clarification of the mechanism of neuroprotection and technical aspects to be 
improved. 
 MSC are adult multipotent stem cells that can be isolated from various tissues, 
including the bone marrow, the first source described for MSC (Caplan, 1991, Friedenstein 
et al., 1970). They are heterogenic cells and it is challenging to isolate a pure cell population 
(Mabuchi et al., 2013). The most commonly used method for MSC isolation is based on their 
plastic adherence feature. Despite that, hematopoietic contaminants may persist in culture, 
especially in the case of MSC isolated from bone marrow of mice (which is the case of the 
present study) as it have been reported that in this species is difficult to remove 
hematopoietic contaminants (Javazon et al., 2004, Phinney et al., 1999). Thus, to isolate a 
more pure MSC population, we performed cell sorting to eliminate CD45+ cells after the 
separation of mononuclear cells. Our results suggest that a relative pure population of MSC 
can be obtained by our isolation method as MSC exhibited a fibroblast-like morphology, 
could grow in a monolayer and accordingly, MSC were negative for the hematopoietic 
markers CD11b and CD45 and highly positive for all the other markers commonly used to 
characterize/identify MSC, such as CD73, CD105, Sca-1, CD29 and CD106 (Baddoo et al., 
2003, Caplan and Dennis, 2006, Morikawa et al., 2009, Sun et al., 2003).  
 We also assessed MSC expression of neural markers in vitro by immunocytochemistry 
and we could observe that MSC already express markers for neuronal/glial cells before 
transplantation, for both immature (nestin) and mature neurons (β-tubulin III and MAP2), 
astrocytes (GFAP), and microglia (Iba-1). This may result from the culture in conditioned 
medium with factors that can influence MSC phenotype. However, MSC kept their 
fibroblastic-like morphology and did not resemble neural/glial cells. These results are in 
accordance with previous observations, which demonstrated that in basal conditions, even in 
the absence of specialized induction agents, MSC already express specific neuronal markers 
(Blondheim et al., 2006, Deng et al., 2006a). Likewise, it has been reported that MSC express 
embryonic stem cells markers (pluripotency markers). Riekstina et al. reported that BM-
MSC express Oct4, Nanog, alkaline phosphatase and SSEA-4 (Riekstina et al., 2009). In 
accordance with this report, we found that in vitro culture conditions, MSC expressed 
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markers for pluripotency, namely Nanog and SSEA-4, which supports the idea that MSC are 
not committed into cells of the neuronal lineage. 
 It has been demonstrated that MSC can graft the nervous tissue and survive for long 
periods of time (Edalatmanesh et al., 2011). In fact, in our study, we could detect MSC 12 
weeks after transplant in the MJD cerebellum, demonstrating that MSC can survive in the 
cerebellar tissue and exert their effect in affected area. 
 The transgenic mouse model used is characterized by Purkinje cell expression of 
truncated form of human ataxin-3 with 69 glutamine repeats and driven by a Purkinje-cell-
specific L7 promoter (Torashima et al., 2008). The cerebellum has an important role in 
maintenance of balance and posture, coordination of voluntary movements and motor 
learning. Therefore, a functional defect in the Purkinje cells can trigger cerebellar ataxia, 
including balance and gait defects (Torashima et al., 2008). Accordingly, at 3 weeks of age, 
transgenic mice already exhibit pronounced ataxia. In this study, animals were injected within 
3-5 weeks of age. Four weeks after transplant, MSC treated mice present a significant 
alleviation of their motor impairments, with better performance in rotarod, swimming and 
footprint tests. Jones et al. demonstrated that mice injected with MSC in the cerebellum 
were capable of walking on the rotarod for longer periods of time than non-treated mice, 
demonstrating that MSC have the potential of alleviating the phenotype in cerebellar ataxias 
for long periods (Jones et al., 2010). In our study, MSC were not able to revert MJD 
phenotype at later time points, which may be explained by the severity of this transgenic 
mice model at this time-point. In future studies, we will assess for MSC transplantation at 
earlier time points in order to investigate whether MSC can revert MJD phenotype at later 
ages. Moreover, multiple injections will also be assessed, as a single injection may not be 
sufficient to provide sustained effects. A clinical trial in China used UC-MSC transplantation 
in patients with MSA-C and SCAs (Dongmei et al., 2011). UC-MSC were injected 
intrathecally weekly, for 4 weeks, meaning that a total of 4 injections were administered in 
each patient. This approach demonstrated to be very promising, as patients presented 
improvements in some MJD symptoms, including unstable walking and standing, slow 
movement, fine motor disorders of the upper limbs, writing difficulties and dysarthria. 
However, in some of the SCA patients (6 of 14), over the period of 1 to 14 months after 
transplantation the disease had progressed, demonstrating that probably repeated injections 
throughout a continuous therapy may be necessary (Dongmei et al., 2011).  
 Importantly, in the future, IV injection of MSC will also be studied to assess the 
neuroprotective competence of MSC using this route of delivery, which would be 
translatable into clinical application within a short time frame. Zhang et al. demonstrated that 
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an ataxic mouse model treated intravenously with human UC-MSC presented better 
performances in rotarod test from 9 weeks until 12 weeks after transplant, proving that IV 
injection of MSC may be an effective approach for other cerebellar ataxias, including MJD 
(Zhang et al., 2011). Besides that, Chang and collaborators compared the IV and IC delivery 
of MSC and concluded that IV transplantation effectively improved rotarod performance of 
SCA2 transgenic mice and delayed the onset of motor function deterioration, while IC 
transplantation failed to achieve such neuroprotective effect (Chang et al., 2011). However, 
in our study we observed motor impairment alleviation, upon local transplantation of MSC. 
In the study of Chang and col. direct IC injection of MSC was performed through foramen 
magnum into cerebellum, while in our study MSC were stereotaxically injected into the 
cerebellum. MSC injections through foramem magnum (through the skull bottom hole) have 
associated risks such as possible surgical lesions, namely in the brainstem. Importantly, the 
authors have performed three injections per animal, accumulating the risks of the invasive 
procedure. Furthermore, this procedure does not allow precise delivery of the cells in a 
specific cerebellar region. Accordingly, the authors have reported that MSC were not 
detected over cerebellar white matter, molecular layer, or the Purkinje cell layer, but were 
limited to a few lumen of blood vessels (Chang et al., 2011). This may explain the failure of 
the therapeutic effect of MSC local delivery in that study, whereas in our study stereotaxic 
cerebellar transplantation of MSC was effective. Nevertheless, we plan to address whether 
the systemic delivery of MSC would be an advantageous alternative in MJD context.   
 It has also has been reported that MSC can alleviate the neuropathology associated to 
cerebellar ataxias. In a study performed in the SCA1 transgenic mouse model, the authors 
demonstrated that MSC injected intrathecally mitigated the cerebellar neuronal 
disorganization. The cerebellum of these SCA1 transgenic mice had ectopically located PC 
bodies that resulted in a multilayer of PC; besides that, mice showed atrophy of the 
cerebellar molecular layer. In the referred study, MSC treated mice displayed a single layer 
of PC and the molecular layer was thicker than that of the untreated mice (Matsuura et al., 
2014).  
 In accordance with these previous reports, we also observed an improvement in the 
MJD associated neuropathology. The transgenic mouse model used presents mutant ataxin-3 
inclusions and severe atrophy of the cerebellum with marked disarrangement of Purkinje 
cells (Torashima et al., 2008). To evaluate the effect of MSC transplantation in the 
neuropathology, we measured both the molecular and the granular layer thicknesses, 
assessed for the number of Purkinje cells and for the number of aggregates at 12 weeks after 
transplants. Treated transgenic mice showed a conservation of both molecular and granular 
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layer, as well as a tendency to preservation of the number of Purkinje cells, however we 
have not observed significant differences in the number of mutant ataxin-3 inclusions. These 
results can indicate that despite the positive correlation between MJD phenotype alleviation 
and the neuroprotective competence of MSC, MSC transplantation was not able to down-
regulate mutant ataxin-3. In future studies, we will assess for both mutant ataxin-3 mRNA 
and protein levels to confirm this paradigm. Inclusion bodies start forming at 40 days 
(Torashima et al., 2008). As such, probably transplantation of MSC at 3-5 weeks may be too 
late to block aggregate formation. Therefore we intend to investigate whether MSC 
transplantation at earlier time points can prevent the formation of intranuclear inclusions. As 
expected, similarly to other reports, in the present study MSC mediated partial recovery of 
cerebellar tissue, supported the survival of the Purkinje cells, and ultimately improved the 
motor functions of mutant mice, after transplantation in cerebellum (Jones et al., 2010).   
 In summary, our results demonstrate that MSC transplantated in situ in the cerebellum 
of MJD transgenic mice engraft and survive in cerebellar tissue. Moreover, MSC can exert a 
positive effect in this MJD model leading to a phenotype alleviation and neuropathological 
improvements. Therefore, transplantation of MSC can become a promising therapy for MJD. 
 
 
5. Conclusion and future perspectives 
In this work it was shown that local transplantation of MSC could alleviate motor 
impairments and cerebellar atrophy, proving that MSC is a good candidate for disease-
modifying MJD therapies. Importantly this experimental paradigm allows thorough 
investigation of the pathways through which MSC transplantation alleviates MJD. 
In order to deepen our knowledge on MSC’s potential effect on MJD, we are presently 
quantifying ataxin-3 down-regulation either by Western blot (allowing assay of both soluble 
and aggregated forms of mutated ataxin-3) and qPCRs from tissue homogenates of the 
cerebellum. Furthermore, as a way of assessing both neuroprotective and 
immunomodulatory MSC potential, we will also measure neurotrophin and ILs levels by 
qPCR. 
In future studies, we will investigate whether MSC´s effect can be even more effective 
and persist for longer periods of time by transplanting MSCs at earlier time points as well as 
by multiple injections. Moreover, systemic delivery of MSC will also be performed in order 
to assess the neuroprotective competence of MSC using this route of delivery, which would 
be translatable into clinical application within a short time frame. 
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6. Supplementary figures 
 
 
Figure S1 - MSC isolation. a) MSC were isolated from femurs and tibias of C57BL/6 wild type mice by bone 
marrow flush and mononuclear cells were separated in a Ficoll density gradient. MSC that did not adhere to 
the plastic were removed 48h after plating and cells were expanded until confluence. b) To get a more pure 
MSC population, the CD45+ cells were eliminated by sorter, using FACS. Adapted from (Willis, 2004). 
Abbreviations: FACS, fluorescence activated cell sorting; MSC, multipotent mesenchymal stromal cells. 
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Figure S2 - In vivo experiments. a)  Schematic representation of the transgene encoding mutant ataxin-3 
under the control of the L7 promoter in the MJD transgenic mice model. Adapted from (Torashima et al., 
2008). b) Diagram illustrating the time line of MSC transplantation and behaviour tests in MJD transgenic mice. 
Mice were injected with 3-5 weeks of age and behaviour test were performed until 12 weeks after transplants. 
Brains were processed and analysed at 12 weeks post-injection. c) Representation of the stereotaxic surgery. 
Panel A - Picture representing the stereotaxic apparatus. The animal is correctly positioned and fixed in the 
stereotaxic apparatus (Panel B), with symmetric position of the head and the nose is able to move freely up and 
down, but lateral movement is constrained by fixation. Adapted from (Cetin et al., 2006). Afterwards, the skin 
is spread apart and the surface of the skull is exposed and the main anatomical landmarks are highlighted: 
bregma and lambda (Panel C). Adapted from (Rynkowski et al., 2008). The initial position is marked in lambda 
and correct coordinates (-1.8 mm rostral to lambda, 0 mm midline, and 1.8 to 2.2 mm ventral to the skull 
surface) are introduced to perform the injection in the cerebellum (Panel D). d) Schematic representation of 
the tank where mice are allowed swimming. e) Schematic representation of hind base width. Abbreviations: 
HA, hemagglutinin; MJD, Machado Joseph disease; MSC, multipotent mesenchymal stromal cells. 
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Figure S3 - Histological processing.  a) Representation of intracardiac perfusion. The animals are 
intracardiacally perfused with PBS followed by fixation with 4% PFA (Panel A). Afterwards, the brain is removed 
(Panel B). Adapted from (Gage et al., 2012). b) Representation of immunohistochemistry. c) Representation of 
cresyl violet staining. Abbreviations: AB, anti-body; DAPI, 4, 6-diamidino-2-phenylindoline; PBS, phosphate 
buffer solution; PFA, paraformaldehyde. 
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